A detailed history of Federated Hermes, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 13,176 shares of ERAS stock, worth $33,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,176
Previous 10,070 30.84%
Holding current value
$33,994
Previous $12,000 133.33%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 03, 2025

BUY
$1.36 - $2.18 $4,224 - $6,771
3,106 Added 30.84%
13,176 $28,000
Q2 2025

Aug 13, 2025

SELL
$1.06 - $1.63 $5,215 - $8,019
-4,920 Reduced 32.82%
10,070 $12,000
Q1 2025

May 08, 2025

SELL
$1.28 - $2.75 $4,380 - $9,410
-3,422 Reduced 18.59%
14,990 $20,000
Q4 2024

Feb 13, 2025

BUY
$2.44 - $3.23 $1,822 - $2,412
747 Added 4.23%
18,412 $46,000
Q3 2024

Nov 13, 2024

BUY
$2.17 - $3.28 $9,498 - $14,356
4,377 Added 32.94%
17,665 $48,000
Q2 2024

Aug 08, 2024

BUY
$1.79 - $2.63 $23,785 - $34,947
13,288 New
13,288 $31,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $315M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.